Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis

Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalidomide-dexamethasone (Len-Dex) (n = 37; years: 2004–...

Descripción completa

Detalles Bibliográficos
Autores principales: Warsame, Rahma, LaPlant, Betsy, Kumar, Shaji K., Laumann, Kristina, Perez Burbano, Gabriela, Buadi, Francis K., Gertz, Morie A., Kyle, Robert A., Lacy, Martha Q., Dingli, David, Leung, Nelson, Hayman, Suzanne R., Kapoor, Prashant, Hwa, Yi L., Fonder, Amie, Hobbs, Miriam, Gonsalves, Wilson I., Kourelis, Taxiarchis, Lust, John, Russell, Stephen J., Zeldenrust, Steven, Lin, Yi, Muchtar, Eli, Go, Ronald S., Vincent Rajkumar, S., Dispenzieri, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949262/
https://www.ncbi.nlm.nih.gov/pubmed/31913261
http://dx.doi.org/10.1038/s41408-019-0266-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949262/
https://www.ncbi.nlm.nih.gov/pubmed/31913261
http://dx.doi.org/10.1038/s41408-019-0266-9

Ejemplares similares